Randomized Study of Efficacy of Different Treatment Regimens of Olokizumab
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the efficacy and safety of Artlegia (INN:
olokizumab) new dosing regimen in patients with moderate coronavirus infection (COVID-19)
with signs of hyperinflammation.
This study is a multicentre, open-label, randomized, comparative, parallel group,
active-controlled clinical trial.
Phase:
Phase 3
Details
Lead Sponsor:
R-Pharm
Collaborators:
Federal Budget Institution of Science "Central Research Institute of Epidemiology" of the Rospotrebnadzor Group of companies Medsi, JSС